Clinical trials: Cerebral Small Vessels Disease
Cerebral Small Vessel Diseases
Investigation of Potential Mechanisms in Stellate Ganglion Block in Individuals With Cerebral Small Vessel Disease
This is a prospective study conducted on patients with Cerebral Small Vessel Disease, dysphagia and cognitive impairment. They were divided into the comparison group and observation group evenly.
- Trial name
- NCT06301711
- Testing
- Rehabilitation therapy, Stellate ganglion block, Lidocaine Hydrochloride
- Volunteers
- 80 people
- Sponsor
- Ahmadu Bello University Teaching Hospital
Fabry Disease, Lysosomal Storage Diseases
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
Fabry disease is a rare, X-linked inborn error of glycosphingolipid metabolism caused by an abnormal gene encoding the α-galactosidase A (αGLA) enzyme.
- Trial name
- NCT04455230
- Testing
- FLT190
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Fabry Disease
Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease
This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific patients with Fabry disease. Treatment is open label.
- Trial name
- NCT01476163
- Testing
- migalastat HCl 150 mg, migalastat HCl 20 mg
- Sponsor
- Amicus Therapeutics
Fabry Disease
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302
This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue…
- Trial name
- NCT07762638
- Testing
- Lucerastat
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Vascular Cognitive Impairment, White Matter Lesions
Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients With White Matter Lesions of Cerebral Small Vessel Disease
The mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease is still unclear. The disrupted synchronization of gamma oscillations in the prefrontal-hippocampal circuit is a potential…
- Conditions
- Vascular Cognitive Impairment, White Matter Lesions, Gamma Oscillation
- Trial name
- NCT07042633
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Fabry Disease
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks.
- Trial name
- NCT04974749
- Testing
- REPLAGAL
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Lysosomal Storage Disorders
Molecular and Cellular Mechanisms of Lysosomal Storage Diseases
The lysosome is a specialized part of the cell that functions to degrade metabolic wastes in the cell. Defects in the functioning of the lysosome result in accumulation and subsequent storage of such metabolic wastes.
- Trial name
- NCT02000310
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- O & O Alpan LLC
Cerebral Small Vessel Diseases
Recovery Improved in Covert Stroke With Exercise
Silent ischemic, also known as "covert stroke vascular disease" (CSVD), contributes to neurological deficits that are caused by damage to small blood vessels in the brain.
- Trial name
- RISE-2 (NCT02068391)
- Testing
- Stretching Program, Exercise Program
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Transcranial Magnetic Stimulation
Effects of High-frequency Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Cerebral Small Vessel Disease
The purpose of this study was to investigate the effect of high-frequency repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with cerebral small vessel disease.
- Trial name
- NCT05914623
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yi Yang
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Cognitive Impairment, Progressive, Cerebral Small Vessel Diseases
Circuit Training and Retina
The purpose of this research study is to see if high-speed weight training performed in a circuit (using one machine after another) can improve participant heart and brain function, strength, and power in older persons.
- Trial name
- NCT05714813
- Testing
- High-Speed Circuit Resistance Training, Lecture on Diet, Exercise and Cognition
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Miami
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA.
- Trial name
- DIETETICA (NCT06933212)
- Testing
- Mediterranean Diet with Extra Virgin Olive Oil, Mediterranean Diet with Walnuts, Low-Fat Control Diet
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Acute Ischemic Stroke, Intracranial Arteriosclerosis
Stroke Imaging Package Study
Our study aims to explore the value of new imaging technique package in predicting early neurological deterioration (END) as well as 90-day unfavorable outcome in patients with acute ischaemic stroke.
- Conditions
- Acute Ischemic Stroke, Intracranial Arteriosclerosis, Cerebral Small Vessel Diseases
- Trial name
- SIPS (NCT02485275)
- Where
- 16 sites in China
- Volunteers
- 949 people
- Sponsor
- Wei-Hai Xu
Autoimmune Diseases, Non-small Cell Lung Cancer
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.
- Conditions
- Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis
- Trial name
- NCT03656627
- Testing
- Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Cerebral Small Vessel Disease and OCT Angio
OCT Angio in Cerebral Small Vessel Disease
The aim of the study is to: - detect changes in retinal structure and microvasculature in patients with cerebral small vessel disease using optical coherence tomography angiography , correlate these changes with brain imaging…
- Trial name
- NCT05052788
- Testing
- Optical coherence tomography angiography
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Anderson-Fabry Disease
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
Anderson Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase. AFD can involve various organs and lead to a series of clinical abnormalities.
- Trial name
- MyFABT1 (NCT02956954)
- Testing
- Enzyme replacement therapy (Agalsidase alpha (Replagal®)), Magnetic Resonance Imaging
- Where
- France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Rouen
Cerebral Small Vessel Diseases
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）
Cerebral small vessel disease is a series of clinical, imaging and pathological syndromes caused by various etiologies affecting the arteries, capillaries, venules in the brain.
- Trial name
- NCT06061692
- Testing
- Tongxinluo Capsule
- Volunteers
- 1,052 people
- Sponsor
- Fudan University
Fabry Disease
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
Prospective, observational cohort study to investigate the prevalence of sleepiness and sleep-related breathing disorders in patients with Fabry disease (FD).
- Trial name
- NCT01947634
- Testing
- ResMed Apnea Link plus
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- University of Zurich